|
HU213221B
(en)
|
1990-03-02 |
1997-03-28 |
Glaxo Group Ltd |
Inhalation device and medicine packet for device
|
|
GB9004781D0
(en)
*
|
1990-03-02 |
1990-04-25 |
Glaxo Group Ltd |
Device
|
|
US6536427B2
(en)
|
1990-03-02 |
2003-03-25 |
Glaxo Group Limited |
Inhalation device
|
|
UA26230A
(en)
|
1990-03-02 |
1999-07-19 |
Глексо Груп Лімітед |
SHARED USER INHALATOR WITH TREATMENT UNIT AND TREATMENT UNIT
|
|
GB9012870D0
(en)
*
|
1990-06-08 |
1990-08-01 |
Glaxo Group Ltd |
Device
|
|
GB9016789D0
(en)
*
|
1990-07-31 |
1990-09-12 |
Lilly Industries Ltd |
Medicament administering devices
|
|
US5042472A
(en)
*
|
1990-10-15 |
1991-08-27 |
Merck & Co., Inc. |
Powder inhaler device
|
|
US5337740A
(en)
*
|
1991-08-01 |
1994-08-16 |
New England Pharmaceuticals, Inc. |
Inhalation devices
|
|
DE19647947A1
(en)
*
|
1996-11-20 |
1998-05-28 |
Pfeiffer Erich Gmbh & Co Kg |
Discharge device for media
|
|
SE9900188D0
(en)
*
|
1999-01-22 |
1999-01-22 |
Astra Ab |
Dispensing device
|
|
US6810872B1
(en)
|
1999-12-10 |
2004-11-02 |
Unisia Jecs Corporation |
Inhalant medicator
|
|
US6759398B2
(en)
|
2000-08-05 |
2004-07-06 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative
|
|
CZ304043B6
(en)
|
2000-08-05 |
2013-09-04 |
Glaxo Group Limited |
Esters of steroidal thioacids
|
|
GB0103630D0
(en)
|
2001-02-14 |
2001-03-28 |
Glaxo Group Ltd |
Chemical compounds
|
|
WO2002076933A1
(en)
|
2001-03-22 |
2002-10-03 |
Glaxo Group Limited |
Formailide derivatives as beta2-adrenoreceptor agonists
|
|
US7291608B2
(en)
|
2001-04-30 |
2007-11-06 |
Glaxo Group Limited |
Anti-inflammatory 17.β.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.α
|
|
US20040244794A1
(en)
*
|
2001-08-09 |
2004-12-09 |
Richards David Hugh |
Inhalation device with a pharmaceutical composition
|
|
BRPI0212455B8
(en)
|
2001-09-14 |
2021-05-25 |
Glaxo Group Ltd |
compound derived from phenethanolamine for the treatment of respiratory diseases, pharmaceutical formulation, combination, and use thereof
|
|
US20030235538A1
(en)
|
2002-04-09 |
2003-12-25 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Method for the administration of an anticholinergic by inhalation
|
|
EP1497261B1
(en)
|
2002-04-25 |
2007-12-19 |
Glaxo Group Limited |
Phenethanolamine derivatives
|
|
GB0217225D0
(en)
|
2002-07-25 |
2002-09-04 |
Glaxo Group Ltd |
Medicinal compounds
|
|
NZ539676A
(en)
|
2002-10-28 |
2006-10-27 |
Glaxo Group Ltd |
Phenethanolamine derivative for the treatment of respiratory diseases
|
|
GB0303396D0
(en)
|
2003-02-14 |
2003-03-19 |
Glaxo Group Ltd |
Medicinal compounds
|
|
AR045914A1
(en)
|
2003-07-17 |
2005-11-16 |
Glaxo Group Ltd |
TERTIARY ALCOHOLIC COMPOUND OF 8-AZONIABICICLO [3.2.1] OCTOBER, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE THIS LAST
|
|
SG147436A1
(en)
|
2003-10-14 |
2008-11-28 |
Glaxo Group Ltd |
Muscarinic acetylcholine receptor antagonists
|
|
EA200600787A1
(en)
|
2003-10-17 |
2006-08-25 |
Глэксо Груп Лимитед |
ANTAGONISTS OF MUSCARINE ACETYL CHOLINE RECEPTORS
|
|
TW200524577A
(en)
|
2003-11-04 |
2005-08-01 |
Glaxo Group Ltd |
Muscarinic acetylcholine receptor antagonists
|
|
GB0329182D0
(en)
|
2003-12-17 |
2004-01-21 |
Glaxo Group Ltd |
Chemical compounds
|
|
WO2005095407A1
(en)
|
2004-03-17 |
2005-10-13 |
Glaxo Group Limited |
M3 muscarinic acetylcholine receptor antagonists
|
|
EP1730104A1
(en)
|
2004-04-02 |
2006-12-13 |
Glaxo Group Limited |
Chemical process and new crystalline form
|
|
MY144753A
(en)
|
2004-04-27 |
2011-10-31 |
Glaxo Group Ltd |
Muscarinic acetylcholine receptor antagonists
|
|
JP2007537261A
(en)
|
2004-05-13 |
2007-12-20 |
グラクソ グループ リミテッド |
Muscarinic acetylcholine receptor antagonist
|
|
US9365905B2
(en)
|
2005-02-10 |
2016-06-14 |
Dmv-Fonterra Excipients Technology Gmbh |
Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
|
|
PE20061351A1
(en)
|
2005-03-25 |
2007-01-14 |
Glaxo Group Ltd |
8H-PYRID [2,3-d] PYRIMIDIN-7-ONA 2,4,8-TRISUSTITUTED COMPOUNDS AS CSBP / RK / p38 KINASE INHIBITORS
|
|
AR053450A1
(en)
|
2005-03-25 |
2007-05-09 |
Glaxo Group Ltd |
DERIVATIVES OF 3,4-DIHYDRO-PYRIMID (4,5-D) PYRIMIDIN-2- (1H) -ONA 1,5,7 TRISUSTITUTED AS INHIBITORS OF QUINASE P38
|
|
WO2007022351A2
(en)
|
2005-08-18 |
2007-02-22 |
Glaxo Group Limited |
Muscarinic acetylcholine receptor antagonists
|
|
AR065804A1
(en)
|
2007-03-23 |
2009-07-01 |
Smithkline Beecham Corp |
COMPOSITE OF INDOL CARBOXAMIDE, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND USE OF THIS COMPOUND TO PREPARE A MEDICINAL PRODUCT
|
|
GB2463451A
(en)
|
2008-09-08 |
2010-03-17 |
Cambridge Lab |
3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
|
|
EP3578169B1
(en)
|
2009-02-26 |
2024-06-26 |
Glaxo Group Limited |
Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
|
|
CA2764830A1
(en)
|
2009-06-16 |
2010-12-23 |
Schering Corporation |
Novel [3,2-c] heteroaryl steroids as glucocorticoid receptor agonists, compositions and uses thereof
|
|
GB0921075D0
(en)
|
2009-12-01 |
2010-01-13 |
Glaxo Group Ltd |
Novel combination of the therapeutic agents
|
|
AU2011298409B2
(en)
|
2010-08-31 |
2013-11-21 |
Glaxo Group Limited |
Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
|
|
US20130157991A1
(en)
|
2010-08-31 |
2013-06-20 |
Osama Ahmed Aswania |
Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties and Methods of Administering the Same
|
|
SG190793A1
(en)
|
2010-11-11 |
2013-07-31 |
Agency Science Tech & Res |
Targeting metabolic enzymes in human cancer
|
|
GB201116641D0
(en)
|
2011-09-27 |
2011-11-09 |
Glaxo Group Ltd |
Novel compounds
|
|
MX2014012989A
(en)
|
2012-04-27 |
2015-01-22 |
Glaxo Group Ltd |
Novel compounds.
|
|
GB201207406D0
(en)
|
2012-04-27 |
2012-06-13 |
Glaxo Group Ltd |
Novel compounds
|
|
CA2891348C
(en)
|
2012-11-28 |
2020-04-28 |
Intercept Pharmaceuticals, Inc. |
Treatment of pulmonary disease
|
|
JP2018509153A
(en)
|
2015-03-11 |
2018-04-05 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
TSLP binding protein
|
|
EP3307729B1
(en)
|
2015-06-15 |
2020-09-02 |
GlaxoSmithKline Intellectual Property Development Limited |
Nrf2 regulators
|
|
RU2018101077A
(en)
|
2015-06-15 |
2019-07-15 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
REGULATORS NRF2
|
|
PH12017502255B1
(en)
|
2015-06-15 |
2022-07-22 |
Astex Therapeutics Ltd |
Nrf2 regulators
|
|
TW201722965A
(en)
|
2015-08-16 |
2017-07-01 |
葛蘭素史密斯克藍智慧財產發展有限公司 |
Compounds for use in antibacterial applications
|
|
JP2018529744A
(en)
|
2015-10-06 |
2018-10-11 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
Arylcyclohexylpyrazoles as NRF2 regulators
|
|
US10364256B2
(en)
|
2015-10-06 |
2019-07-30 |
Glaxosmithkline Intellectual Property Development Limited |
Biaryl pyrazoles as NRF2 regulators
|
|
EP3515889A1
(en)
|
2016-09-20 |
2019-07-31 |
GlaxoSmithKline Intellectual Property (No. 2) Limited |
Trpv4 antagonists
|
|
TW201825458A
(en)
|
2016-09-20 |
2018-07-16 |
英商葛蘭素史克智慧財產(第二)有限公司 |
TRPV 4 antagonists
|
|
JP7106528B2
(en)
|
2016-09-20 |
2022-07-26 |
グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッド |
TRPV4 antagonist
|
|
KR20190088404A
(en)
|
2016-12-06 |
2019-07-26 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
3- (2,3-dihydro-1H-inden-5-yl) propanoic acid derivatives and their use as NRF2 regulators
|
|
JP2020500918A
(en)
|
2016-12-12 |
2020-01-16 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
N-arylpyrazoles as NRF2 regulators
|
|
US20200031820A1
(en)
|
2016-12-12 |
2020-01-30 |
Glsxosmithkline Intellectual Property Development Limited |
3-carboxylic acid pyrroles as nrf2 regulators
|
|
WO2018109643A1
(en)
|
2016-12-14 |
2018-06-21 |
Glaxosmithkline Intellectual Property Development Limited |
Bisaryl heterocycles as nrf2 acti
|
|
JP2020502129A
(en)
|
2016-12-14 |
2020-01-23 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
3-oxo-1,4-diazepinyl compounds as NRF2 activators
|
|
ES2901617T3
(en)
|
2016-12-14 |
2022-03-23 |
Glaxosmithkline Ip Dev Ltd |
Bisarylamides as regulators of NRF2
|
|
US11059816B2
(en)
|
2016-12-15 |
2021-07-13 |
Glaxosmithkline Intellectual Property Development Limited |
Ether linked triazoles as NRF2 activators
|
|
WO2018109646A1
(en)
|
2016-12-15 |
2018-06-21 |
Glaxosmithkline Intellectual Property Development Limited |
Nrf2 compounds
|
|
PH12019502376B1
(en)
|
2017-04-24 |
2024-06-05 |
Cocrystal Pharma Inc |
Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
|
|
EP3723764A1
(en)
|
2017-12-11 |
2020-10-21 |
GlaxoSmithKline Intellectual Property Development Ltd |
Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
|
|
WO2019116231A1
(en)
|
2017-12-11 |
2019-06-20 |
Glaxosmithkline Intellectual Property Development Limited |
Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
|
|
GB201720989D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
TWI795510B
(en)
|
2018-01-17 |
2023-03-11 |
英商葛蘭素史密斯克藍智慧財產發展有限公司 |
PI4KIIIβ INHIBITORS
|
|
US11643407B2
(en)
|
2018-05-23 |
2023-05-09 |
Glaxosmithkline Intellectual Property Development Limited |
Indanes as NRF2 activators
|
|
KR102813547B1
(en)
|
2018-07-27 |
2025-05-27 |
코크리스탈 파마, 아이엔씨. |
Pyrrolo[2,3-b]pyridine derivatives as influenza virus replication inhibitors
|
|
CN113286793B
(en)
|
2018-09-10 |
2024-04-05 |
共结晶制药公司 |
Inhibitors of influenza virus replication of pyrrolopyrazines and pyridotriazines
|
|
AU2019361038B2
(en)
|
2018-10-17 |
2025-07-03 |
Cocrystal Pharma, Inc. |
Combinations of inhibitors of influenza virus replication
|
|
JP7706362B2
(en)
|
2018-11-13 |
2025-07-11 |
コクリスタル ファーマ,インコーポレイテッド |
Influenza drug formulation
|
|
WO2020112716A1
(en)
|
2018-11-26 |
2020-06-04 |
Cocrystal Pharma, Inc. |
Inhibitors of influenza virus replication
|
|
GB201908536D0
(en)
|
2019-06-13 |
2019-07-31 |
Glaxosmithkline Ip Dev Ltd |
Compounds
|
|
WO2021188620A1
(en)
|
2020-03-17 |
2021-09-23 |
Cocrystal Pharma Inc. |
Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replication
|
|
JP7721561B2
(en)
|
2020-04-10 |
2025-08-12 |
コクリスタル ファーマ,インコーポレイテッド |
Inhibitors of norovirus and coronavirus replication
|
|
US20230158125A1
(en)
|
2020-04-20 |
2023-05-25 |
Sorrento Therapeutics, Inc. |
Pulmonary Administration of ACE2 Polypeptides
|
|
WO2022175425A1
(en)
|
2021-02-22 |
2022-08-25 |
Glaxosmithkline Intellectual Property Development Limited |
Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection
|
|
WO2022179967A1
(en)
|
2021-02-23 |
2022-09-01 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Vadadustat for treating covid-19 in a hospitalized subject
|
|
CA3227602A1
(en)
|
2021-08-03 |
2023-02-09 |
Irina C. Jacobson |
Inhibitors for coronaviruses
|